Asclepius International Journal of Scientific Health Science · Jun 13, 2026
HORMONE THERAPY IN MENOPAUSE: EVALUATION OF BENEFITS AND RISKS
By Filho CRDD, Freitas LKR, de Lacerda SRG
INTRODUCTION: Menopause hormone therapy is the most effective intervention for the relief of vasomotor symptoms and prevention of bone loss. However, the publication of landmark clinical trials generated controversies regarding cardiovascular safety and the risk of neoplasms, demanding a constant reassessment of eligibility criteria in clinical practice. OBJECTIVE: To evaluate current scientific evidence on the benefits and risks of menopause hormone therapy, focusing on therapeutic individualization. METHODS: Integrative literature review in the PubMed, SciELO, and LILACS databases. A total of 25 articles published between 2020 and 2026 were selected, in English, Spanish, and Portuguese, encompassing clinical trials, meta-analyses, and consensus guidelines. RESULTS AND DISCUSSION: The results demonstrate that efficacy in controlling vasomotor symptoms exceeds eighty percent. The therapeutic window of opportunity establishes that the initiation of therapy in women under sixty years of age or within ten years after menopause presents a favorable cardiovascular profile (MANSON et al., 2017). The risk of venous thromboembolism is minimized by the transdermal route. Regarding breast cancer, the risk is associated with prolonged combined regimens, whereas estrogen-only therapy in hysterectomized patients presents a superior safety profile (THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022). CONCLUSIONS: The benefits of hormone therapy outweigh the risks for the majority of symptomatic women in early postmenopause. Medical management should focus on the judicious choice of administration route, dose, and duration of use, ensuring maximum safety and improvement in quality of life.